Pfizer (PFE.US) Plans $5 Billion Bond Issuance to Fund Acquisition of Obesity Drugmaker Metsera

Stock News11-19

Pfizer (PFE.US) is planning to raise at least $5 billion through a U.S. dollar corporate bond offering, with part of the proceeds earmarked to finance its recent acquisition of obesity drug developer Metsera Inc. (MTSR), according to sources familiar with the matter. The New York-based pharmaceutical giant intends to issue the bonds in up to seven tranches.

Insiders revealed that the longest-dated 40-year bonds are initially priced at a spread of approximately 1.25 percentage points above U.S. Treasury yields. The bond issuance was launched on Tuesday alongside eight other investment-grade corporate debt offerings. This follows a $26.3 billion financing day in the market, driven by Amazon's (AMZN.US) $15 billion investment-grade bond sale the previous day.

Pfizer secured the acquisition of Metsera after a competitive bidding process, with the total deal value reaching up to $10 billion. The transaction includes a contingent value right component, offering an additional $20.65 per share in cash payments. The bond proceeds will also be used for general corporate purposes and refinancing existing debt.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192752473?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 11:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192752473","market":"hk","top_or_hot":-1,"title":"Pfizer (PFE.US) Plans $5 Billion Bond Issuance to Fund Acquisition of Obesity Drugmaker Metsera","media":"Stock News","content":"<p>Pfizer (PFE.US) is planning to raise at least $5 billion through a U.S. dollar corporate bond offering, with part of the proceeds earmarked to finance its recent acquisition of obesity drug developer Metsera Inc. (MTSR), according to sources familiar with the matter. The New York-based pharmaceutical giant intends to issue the bonds in up to seven tranches.</p>\n<p>Insiders revealed that the longest-dated 40-year bonds are initially priced at a spread of approximately 1.25 percentage points above U.S. Treasury yields. The bond issuance was launched on Tuesday alongside eight other investment-grade corporate debt offerings. This follows a $26.3 billion financing day in the market, driven by Amazon's (AMZN.US) $15 billion investment-grade bond sale the previous day.</p>\n<p>Pfizer secured the acquisition of Metsera after a competitive bidding process, with the total deal value reaching up to $10 billion. The transaction includes a contingent value right component, offering an additional $20.65 per share in cash payments. The bond proceeds will also be used for general corporate purposes and refinancing existing debt.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer (PFE.US) Plans $5 Billion Bond Issuance to Fund Acquisition of Obesity Drugmaker Metsera</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer (PFE.US) Plans $5 Billion Bond Issuance to Fund Acquisition of Obesity Drugmaker Metsera\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-19 11:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer (PFE.US) is planning to raise at least $5 billion through a U.S. dollar corporate bond offering, with part of the proceeds earmarked to finance its recent acquisition of obesity drug developer Metsera Inc. (MTSR), according to sources familiar with the matter. The New York-based pharmaceutical giant intends to issue the bonds in up to seven tranches.</p>\n<p>Insiders revealed that the longest-dated 40-year bonds are initially priced at a spread of approximately 1.25 percentage points above U.S. Treasury yields. The bond issuance was launched on Tuesday alongside eight other investment-grade corporate debt offerings. This follows a $26.3 billion financing day in the market, driven by Amazon's (AMZN.US) $15 billion investment-grade bond sale the previous day.</p>\n<p>Pfizer secured the acquisition of Metsera after a competitive bidding process, with the total deal value reaching up to $10 billion. The transaction includes a contingent value right component, offering an additional $20.65 per share in cash payments. The bond proceeds will also be used for general corporate purposes and refinancing existing debt.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"","article_id":"1192752473","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192752473","pubTimestamp":1763521458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Pfizer (PFE.US) is planning to raise at least $5 billion through a U.S. dollar corporate bond offering, with part of the proceeds earmarked to finance its recent acquisition of obesity drug developer...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4592":"伊斯兰概念","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4568":"美国抗疫概念","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4550":"红杉资本持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4588":"碎股","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4007":"制药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4581":"高盛持仓","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4599":"减肥药","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","PFE":"辉瑞","BK4139":"生物科技","MTSR":"Metsera Inc.","SG9999001176.USD":"United Global Healthcare Acc USD"},"translate_title":"辉瑞(PFE.US)计划发行50亿美元债券为收购肥胖药商Metsera提供资金","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1,"MTSR":1},"content_text":"Pfizer (PFE.US) is planning to raise at least $5 billion through a U.S. dollar corporate bond offering, with part of the proceeds earmarked to finance its recent acquisition of obesity drug developer Metsera Inc. (MTSR), according to sources familiar with the matter. The New York-based pharmaceutical giant intends to issue the bonds in up to seven tranches.\nInsiders revealed that the longest-dated 40-year bonds are initially priced at a spread of approximately 1.25 percentage points above U.S. Treasury yields. The bond issuance was launched on Tuesday alongside eight other investment-grade corporate debt offerings. This follows a $26.3 billion financing day in the market, driven by Amazon's (AMZN.US) $15 billion investment-grade bond sale the previous day.\nPfizer secured the acquisition of Metsera after a competitive bidding process, with the total deal value reaching up to $10 billion. The transaction includes a contingent value right component, offering an additional $20.65 per share in cash payments. The bond proceeds will also be used for general corporate purposes and refinancing existing debt.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192752473","isCrawlerRequest":true}